Therapeutic vulnerabilities of mesenchymal subpopulations of pancreatic cancer cells undergoing anabolic reprogramming
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus musculus
PROVIDER: GSE83754 | GEO | 2017/02/13
SECONDARY ACCESSION(S): PRJNA326925
REPOSITORIES: GEO
Similar Datasets
Project description:Malignant neoplasms adapt and evolve in response to changes in oncogenic signaling, tumor microenvironmental stresses,and therapeutic interventions. Cancer cell plasticity in response to these evolutionary pressures is foundational to tumor progression and maintenance and therapeutic resistance. Here, to elucidate the underlying molecular and cellularmechanisms of cancer cell plasticity, integrated system-level, functional and genetic analyses were conducted in a conditional oncogenic Kras model of pancreatic ductal adenocarcinoma (PDAC), amalignancy displaying remarkable phenotypic diversityand morphological heterogeneity. In this model, stochastic extinction of oncogenic Krassignaling and emergence ofKras-independent escaper populationsis associated withde-differentiation and aggressive biological behavior.Transcriptomic and functional analyses ofKras-independent escapers reveal mesenchymal reprogramming driven by aSmarcb1/Mycnetwork and independence from MAPK signaling.A somatic mosaic model of PDAC which can track evolving subpopulations shows that depletion of Smarcb1 activates theMyc network which results in an anabolic switch to increased protein metabolism and the adaptive activation of ERstress-induced survival pathways.Theelevated protein turnover made mesenchymal sub-populationshighly susceptible topharmacological and genetic perturbation of the cellular proteostatic machinery andthe IRE1-α/MKK4 arm of the ER stress response pathway. Specifically, combination regimens impairing the unfolded protein responses (UPR) and the ER stress response can block the emergence of aggressive mesenchymal subpopulations in murine andpatient-derived PDACmodels. These molecular and biological insights inform a potential therapeutic strategy fortargeting aggressive mesenchymal features of PDAC.
2017-02-13 | GSE83753 | GEO
Project description:Malignant neoplasms adapt and evolve in response to changes in oncogenic signaling, tumor microenvironmental stresses,and therapeutic interventions. Cancer cell plasticity in response to these evolutionary pressures is foundational to tumor progression and maintenance and therapeutic resistance. Here, to elucidate the underlying molecular and cellularmechanisms of cancer cell plasticity, integrated system-level, functional and genetic analyses were conducted in a conditional oncogenic Kras model of pancreatic ductal adenocarcinoma (PDAC), amalignancy displaying remarkable phenotypic diversityand morphological heterogeneity. In this model, stochastic extinction of oncogenic Krassignaling and emergence ofKras-independent escaper populationsis associated withde-differentiation and aggressive biological behavior.Transcriptomic and functional analyses ofKras-independent escapers reveal mesenchymal reprogramming driven by aSmarcb1/Mycnetwork and independence from MAPK signaling.A somatic mosaic model of PDAC which can track evolving subpopulations shows that depletion of Smarcb1 activates theMyc network which results in an anabolic switch to increased protein metabolism and the adaptive activation of ERstress-induced survival pathways.Theelevated protein turnover made mesenchymal sub-populationshighly susceptible topharmacological and genetic perturbation of the cellular proteostatic machinery andthe IRE1-α/MKK4 arm of the ER stress response pathway. Specifically, combination regimens impairing the unfolded protein responses (UPR) and the ER stress response can block the emergence of aggressive mesenchymal subpopulations in murine andpatient-derived PDACmodels. These molecular and biological insights inform a potential therapeutic strategy fortargeting aggressive mesenchymal features of PDAC.
2017-02-13 | GSE83752 | GEO
Project description:Therapeutic vulnerabilities of mesenchymal subpopulations of pancreatic cancer cells undergoing anabolic reprogramming
| PRJNA326925 | ENA
Project description:Malignant neoplasms evolve in response to changes in oncogenic signalling. Cancer cell plasticity in response to evolutionary pressures is fundamental to tumour progression and the development of therapeutic resistance. Here we determine the molecular and cellular mechanisms of cancer cell plasticity in a conditional oncogenic Kras mouse model of pancreatic ductal adenocarcinoma (PDAC), a malignancy that displays considerable phenotypic diversity and morphological heterogeneity. In this model, stochastic extinction of oncogenic Kras signalling and emergence of Kras-independent escaper populations (cells that acquire oncogenic properties) are associated with de-differentiation and aggressive biological behaviour. Transcriptomic and functional analyses of Kras-independent escapers reveal the presence of Smarcb1-Myc-network-driven mesenchymal reprogramming and independence from MAPK signalling. A somatic mosaic model of PDAC, which allows time-restricted perturbation of cell fate, shows that depletion of Smarcb1 activates the Myc network, driving an anabolic switch that increases protein metabolism and adaptive activation of endoplasmic-reticulum-stress-induced survival pathways. Increased protein turnover renders mesenchymal sub-populations highly susceptible to pharmacological and genetic perturbation of the cellular proteostatic machinery and the IRE1-?-MKK4 arm of the endoplasmic-reticulum-stress-response pathway. Specifically, combination regimens that impair the unfolded protein responses block the emergence of aggressive mesenchymal subpopulations in mouse and patient-derived PDAC models. These molecular and biological insights inform a potential therapeutic strategy for targeting aggressive mesenchymal features of PDAC.
| S-EPMC7609022 | biostudies-literature
Project description:During the progression of pancreatic ductal adenocarcinoma (PDAC), heterogeneous subclonal populations emerge that drive primary tumor growth, regional spread, distant metastasis, and patient death. However, the genetics of metastases largely reflects that of the primary tumor in untreated patients, and PDAC driver mutations are shared by all subclones. This raises the possibility that an epigenetic process might operate during metastasis. Here we report large-scale reprogramming of chromatin modifications during the natural evolution of distant metastasis. Changes were targeted to thousands of large chromatin domains across the genome that collectively specified malignant traits, including euchromatin and large organized chromatin histone H3 lysine 9 (H3K9)-modified (LOCK) heterochromatin. Remarkably, distant metastases co-evolved a dependence on the oxidative branch of the pentose phosphate pathway (oxPPP), and oxPPP inhibition selectively reversed reprogrammed chromatin, malignant gene expression programs, and tumorigenesis. These findings suggest a model whereby linked metabolic-epigenetic programs are selected for enhanced tumorigenic fitness during the evolution of distant metastasis.
| S-EPMC5695682 | biostudies-literature
Project description:Due to loss of p16ink4a in pancreatic ductal adenocarcinoma (PDA), pharmacological suppression of CDK4/6 could represent a potent target for treatment. In PDA models, CDK4/6 inhibition had a variable effect on cell cycle but yielded accumulation of ATP and mitochondria. Pharmacological CDK4/6 inhibitors induce cyclin D1 protein levels; however, RB activation was required and sufficient for mitochondrial accumulation. CDK4/6 inhibition stimulated glycolytic and oxidative metabolism and was associated with an increase in mTORC1 activity. MTOR and MEK inhibitors potently cooperate with CDK4/6 inhibition in eliciting cell-cycle exit. However, MTOR inhibition fully suppressed metabolism and yielded apoptosis and suppression of tumor growth in xenograft models. The metabolic state mediated by CDK4/6 inhibition increases mitochondrial number and reactive oxygen species (ROS). Concordantly, the suppression of ROS scavenging or BCL2 antagonists cooperated with CDK4/6 inhibition. Together, these data define the impact of therapeutics on PDA metabolism and provide strategies for converting cytostatic response to tumor cell killing.
| S-EPMC4757440 | biostudies-literature
Project description:Pancreatic ductal adenocarcinoma (PDAC) harbors the worst prognosis of any common solid tumor, and multiple failed clinical trials indicate therapeutic recalcitrance. Here, we use exome sequencing of patient tumors and find multiple conserved genetic alterations. However, the majority of tumors exhibit no clearly defined therapeutic target. High-throughput drug screens using patient-derived cell lines found rare examples of sensitivity to monotherapy, with most models requiring combination therapy. Using PDX models, we confirmed the effectiveness and selectivity of the identified treatment responses. Out of more than 500 single and combination drug regimens tested, no single treatment was effective for the majority of PDAC tumors, and each case had unique sensitivity profiles that could not be predicted using genetic analyses. These data indicate a shortcoming of reliance on genetic analysis to predict efficacy of currently available agents against PDAC and suggest that sensitivity profiling of patient-derived models could inform personalized therapy design for PDAC.
| S-EPMC5287055 | biostudies-literature
Project description:Receptor tyrosine kinase (RTK) pathways serve as frequent oncogene drivers in solid cancers and small molecule and antibody-based inhibitors have been developed as targeted therapeutics for many of these oncogenic RTKs. In general, these drugs, when delivered as single agents in a manner consistent with the principles of precision medicine, induce tumor shrinkage but rarely complete tumor elimination. Moreover, acquired resistance of treated tumors is nearly invariant such that monotherapy strategies with targeted RTK drugs fail to provide long-term control or cures. The mechanisms mediating acquired resistance in tumors at progression treated with RTK inhibitors are relatively well defined compared to the molecular and cellular understanding of the cancer cells that persist early on therapy. We and others propose that these persisting cancer cells, termed "residual disease", provide the reservoir from which acquired resistance eventually emerges. Herein, we will review the literature that describes rapid reprogramming induced upon inhibition of oncogenic RTKs in cancer cells as a mechanism by which cancer cells persist to yield residual disease and consider strategies for disrupting these intrinsic responses for future therapeutic gain.
| S-EPMC5817864 | biostudies-literature
Project description:This SuperSeries is composed of the SubSeries listed below.
2020-10-01 | GSE158787 | GEO
Project description:Inactivation of tumour-suppressor genes by homozygous deletion is a prototypic event in the cancer genome, yet such deletions often encompass neighbouring genes. We propose that homozygous deletions in such passenger genes can expose cancer-specific therapeutic vulnerabilities when the collaterally deleted gene is a member of a functionally redundant family of genes carrying out an essential function. The glycolytic gene enolase 1 (ENO1) in the 1p36 locus is deleted in glioblastoma (GBM), which is tolerated by the expression of ENO2. Here we show that short-hairpin-RNA-mediated silencing of ENO2 selectively inhibits growth, survival and the tumorigenic potential of ENO1-deleted GBM cells, and that the enolase inhibitor phosphonoacetohydroxamate is selectively toxic to ENO1-deleted GBM cells relative to ENO1-intact GBM cells or normal astrocytes. The principle of collateral vulnerability should be applicable to other passenger-deleted genes encoding functionally redundant essential activities and provide an effective treatment strategy for cancers containing such genomic events.
| S-EPMC3712624 | biostudies-literature